Shimoni A, Peczynski C, Labopin M, Kulagin A, Meijer E, Cornelissen J
Leukemia. 2024; 39(1):222-228.
PMID: 39482353
PMC: 11717700.
DOI: 10.1038/s41375-024-02445-x.
Dean D, Sroussi H
Front Oral Health. 2022; 3:903154.
PMID: 35719318
PMC: 9205403.
DOI: 10.3389/froh.2022.903154.
Khan S, Gerber D
Semin Cancer Biol. 2019; 64:93-101.
PMID: 31330185
PMC: 6980444.
DOI: 10.1016/j.semcancer.2019.06.012.
McCurdy S, Kanakry C, Tsai H, Gojo I, Smith B, Gladstone D
Biol Blood Marrow Transplant. 2019; 25(6):1128-1135.
PMID: 30599208
PMC: 6559825.
DOI: 10.1016/j.bbmt.2018.12.767.
McCurdy S, Kanakry C, Tsai H, Kasamon Y, Showel M, Bolanos-Meade J
Biol Blood Marrow Transplant. 2017; 24(2):343-352.
PMID: 29055682
PMC: 6464126.
DOI: 10.1016/j.bbmt.2017.10.023.
Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention.
Al-Kadhimi Z, Gul Z, Abidi M, Lum L, Deol A, Chen W
Bone Marrow Transplant. 2017; 52(9):1304-1310.
PMID: 28581472
PMC: 6857176.
DOI: 10.1038/bmt.2017.95.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.
Boyiadzis M, Bishop M, Abonour R, Anderson K, Ansell S, Avigan D
J Immunother Cancer. 2016; 4:90.
PMID: 28018601
PMC: 5168808.
DOI: 10.1186/s40425-016-0188-z.
Umbilical Cord Blood Transplantation-associated Nephrotic Syndrome Successfully Treated by Low-density Lipoprotein Apheresis.
Sugawara Y, Honda K, Katagiri D, Nakamura M, Kawakami T, Nasu R
Intern Med. 2016; 55(19):2831-2836.
PMID: 27725544
PMC: 5088545.
DOI: 10.2169/internalmedicine.55.7017.
Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis.
Mielke S, Lutz M, Schmidhuber J, Kapp M, Ditz D, Ammer J
Bone Marrow Transplant. 2014; 49(11):1412-8.
PMID: 25089598
DOI: 10.1038/bmt.2014.170.
Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD.
Zeng Y, Stokes J, Hahn S, Hoffman E, Katsanis E
Bone Marrow Transplant. 2014; 49(8):1076-83.
PMID: 24777185
DOI: 10.1038/bmt.2014.91.
Hematopoietic stem cell transplantation for the management of follicular lymphoma.
Hosing C
Stem Cells Cloning. 2013; 3:69-80.
PMID: 24198512
PMC: 3781727.
DOI: 10.2147/sccaa.s7014.
Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.
Qin L, Smith B, Tsai H, Yaghi N, Neela P, Moake M
Blood Cancer J. 2013; 3:e145.
PMID: 24013666
PMC: 3789208.
DOI: 10.1038/bcj.2013.44.
Allogeneic hematopoietic cell transplantation: the state of the art.
Gyurkocza B, Rezvani A, Storb R
Expert Rev Hematol. 2010; 3(3):285-99.
PMID: 20871781
PMC: 2943393.
DOI: 10.1586/ehm.10.21.
Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study.
Slavin S, Ackerstein A, Or R, Shapira M, Gesundheit B, Askenasy N
Cancer Immunol Immunother. 2010; 59(10):1511-9.
PMID: 20563804
PMC: 11031035.
DOI: 10.1007/s00262-010-0878-1.
Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.
Ramakrishnan A, Sandmaier B
Expert Rev Hematol. 2010; 3(1):23-33.
PMID: 20383269
PMC: 2850074.
DOI: 10.1586/ehm.09.73.
Pathogenesis and management of graft-versus-host disease.
Choi S, Levine J, Ferrara J
Immunol Allergy Clin North Am. 2010; 30(1):75-101.
PMID: 20113888
PMC: 4141413.
DOI: 10.1016/j.iac.2009.10.001.
The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells.
Symons H, Levy M, Wang J, Zhou X, Zhou G, Cohen S
Biol Blood Marrow Transplant. 2008; 14(5):499-509.
PMID: 18410892
PMC: 2377414.
DOI: 10.1016/j.bbmt.2008.02.013.
Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans.
Robin M, Schlageter M, Chomienne C, Padua R
Cancer Immunol Immunother. 2005; 54(10):933-43.
PMID: 15889256
PMC: 11034191.
DOI: 10.1007/s00262-005-0678-1.
Graft-versus-host disease, the graft-versus-leukemia effect, and mixed chimerism following nonmyeloablative stem cell transplantation.
Slavin S
Int J Hematol. 2003; 78(3):195-207.
PMID: 14604277
DOI: 10.1007/BF02983795.
The new stem cell biology.
Quesenberry P, Colvin G, Lambert J, Frimberger A, Dooner M, McAuliffe C
Trans Am Clin Climatol Assoc. 2002; 113:182-206; discussion 206-7.
PMID: 12053709
PMC: 2194475.
